Matthias M, Saul G
Onkologie. 1978 Feb;1(1):41-4. doi: 10.1159/000213910.
The urinary excretion of alkylating CP metabolites was measured in 33 tumor patients by using NPB-test under consideration of different doses, routes of administration (i.v. and i.m.) and function of the liver and the kidney. There was no limit in activation capacity with increased doses of CP. The estimation of the upper activation limit was hindered by the host's subjective toxicity. CP was activated in a comparable manner after i.v. or i.m. administration. It is of interest that liver involvement by the disease or functionally compensated post-nephrectomy state of patients investigated so far did not diminish the excretion of alkylating CP metabolites.
在33例肿瘤患者中，考虑到不同剂量、给药途径（静脉注射和肌肉注射）以及肝肾功能，采用NPB试验测量了烷化CP代谢产物的尿排泄量。随着CP剂量的增加，活化能力没有限制。宿主的主观毒性阻碍了对活化上限的估计。静脉注射或肌肉注射后，CP的活化方式相当。有趣的是，迄今为止所研究患者的疾病所致肝脏受累或肾切除术后功能代偿状态并未减少烷化CP代谢产物的排泄。
